PTIXProtagenic Therapeutics, Inc.\new
Health Care
Operating Income (Loss) revised up 48.5% for Q1 2025
This is the 7th largest revision in PTIX's history.
Operating Income (Loss)·Q1 2025
Major restatement-$1.2M▲ 48.5%
was-$2.3M
Revised up in a 10-Q.
Verify against SEC filingsShow
As reported-$2.3M
Accepted 2025-09-100001641172-25-027041
Restated-$1.2M
Accepted 2026-08-190001493152-26-039221
OperatingIncome · reported 2 times · point-in-time, survivorship-free. Every figure traces to its filing above.
Track this the moment it happens
Get a signal the next time PTIX — or any company on your watchlist — restates a number. Every signal lands with the diff and its source filing.